Measuring Absolute Brain Flow and Brain Microcirculation Resistance by Continuous Thermodilution: a Pilot Study
RESISTANCE
1 other identifier
interventional
15
1 country
1
Brief Summary
Worldwide, cerebrovascular accidents (also known as strokes) are the leading cause of acquired disability, the second-leading cause of dementia (after Alzheimer's disease) and the second-leading cause of death (but the leading cause of death among women). A mechanical thrombectomy (MT) allows the recanalization of the occluded cerebral artery during an acute ischemic stroke, by removing the blood clot with a mechanical device inserted endovascularly under image guidance. MTs are the optimal treatment for a large number of patients presenting an occlusion in an anterior artery (the internal carotid artery and the proximal segment of the middle cerebral artery). Reperfusion is considered satisfactory if the mTICI score at the end of the procedure is of mTICI 2c or mTICI 3. Despite these scores having been obtained by 71% of patients during the randomized trials, showing the superiority of MT over intravenous thrombolysis, only 27% of these patients were free of neurological deficits at 3 months . Therefore, there is a discrepancy between the high rate of macroscopic recanalization and clinical results. One hypothesis to explain this discrepancy is that despite high quality macroscopic recanalization, reperfusion of the cerebral microcirculation remains insufficient: macroscopic recanalization is not equivalent to microscopic reperfusion. This discrepancy also exists in cardiology: despite a high rate of coronary artery recanalization when patients with an ST- segment elevation myocardial infarction are in emergency care, half of these patients later exhibit coronary microvascular dysfunction. The absence of reperfusion is associated with an increased risk of cardiovascular death, recurring myocardial infarctions, cardiogenic shock and heart failure one year after the coronary recanalization for an ST-segment elevation myocardial infarction. It has been shown that continuous intracoronary thermodilution can be used to quantify coronary blood flow and the absolute value of microcirculatory resistance (in Wood units). There are not currently any tools that can quantify cerebral microcirculation immediately after an MT. The aim of this study is to evaluate the feasibility and safety of using a pressure/temperature sensing guidewire to measure cerebral microcirculatory resistance using thermodilution in patients with a score of mTICI 2c or 3 after MT for the management of acute ischemic stroke in the anterior circulation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Apr 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 6, 2026
CompletedStudy Start
First participant enrolled
April 7, 2026
CompletedFirst Posted
Study publicly available on registry
May 5, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 1, 2027
May 5, 2026
April 1, 2026
1.1 years
February 6, 2026
April 27, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
The primary objective is to assess the feasibility of measuring cerebral blood flow and cerebral microcirculatory resistance using thermodilution with the rayflow microcatheter and pressurewire guide.
The primary evaluation criterion is the proportion of patients for whom measurements of cerebral blood flow and cerebral microcirculatory resistance using thermodilution were possible.
Immediately after the measurement of cerebral blood flow and cerebral microcirculatory resistance using thermodilution done with the pressure temperature guidewire
Secondary Outcomes (4)
To assess the safety of using thermodilution to measure cerebral blood flow and cerebral microcirculatory resistance
Immediately after the measurement of cerebral blood flow and cerebral microcirculatory resistance using thermodilution done with the pressure temperature guidewire
To describe the clinical evolution of patients
DAY 90
Determine the threshold value of the cerebral microcirculation resistance index that allows the definition of an optimal sensitivity/specificity pair for the prognosis of neurological progression (favorable or not).
day 90
Measure the additional radiation dose received by patient
day 1
Study Arms (1)
fully recanalization
EXPERIMENTALInterventions
The measurements will be taken as follows: once satisfactory recanalization has been achieved (mTICI 2c or 3), the suction catheter will be placed at the origin of the M1 segment. Through this catheter, the pressure/temperature measurement microguide will be placed at the distal part of M1. The microcatheter will be placed on the microguide, with its tip positioned at the outlet of the aspiration catheter. A pressure sensor will be connected to the aspiration catheter. The microcatheter will be connected to the saline injector programmed to inject saline. The microguide is replaced in the microcatheter 165 seconds after the start of the injection. The trace of the variation in parameters will be recorded on the Coroventis station. A control injection will be performed after removal of the microcatheter and microguide from the suction catheter to ensure that there are no complications due to the measurement.
Eligibility Criteria
You may qualify if:
- Men or women aged 18 to 80
- Social Security beneficiaries
- Obtained signed consent to participate in the study
- TICI 2c or TICI 3 score after mechanical thrombectomy
- Patients hospitalized for ischemic stroke due to middle cerebral artery thrombosis
You may not qualify if:
- Spasm of an artery without significant stenosis
- Vessel diameter less than 1 mm
- Severe visceral failure
- Local infection
- Minors
- Adults protected by law
- Patients deprived of their liberty
- Subjects who are uncooperative or unable to meet the requirements of the protocol
- Pregnant women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU de NICE
Nice, Alpes-maritimes, 06000, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DEVICE FEASIBILITY
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 6, 2026
First Posted
May 5, 2026
Study Start
April 7, 2026
Primary Completion (Estimated)
May 1, 2027
Study Completion (Estimated)
November 1, 2027
Last Updated
May 5, 2026
Record last verified: 2026-04